| Cynthia Lois Tillery Richardson, MSCCCSLP | |
|
4200 Murfreesboro Pike, Antioch, TN 37013-2789 | |
| (615) 501-3529 | |
| (615) 501-3702 |
| Full Name | Cynthia Lois Tillery Richardson |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 4200 Murfreesboro Pike, Antioch, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801582499 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 1322 (Tennessee) | Primary |
| Provider Name | Empowerme Rehabilitation Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1467023861 PECOS PAC ID: 2769723162 Enrollment ID: O20210928002596 |
News Archive
The World Health Organization (WHO) Goodwill Ambassador for Maternal, Newborn and Child Health and supermodel Liya Kebede has highlighted the plight of millions of women and girls living with obstetric fistula.
Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.
Regular prescribing of antibiotics to children in the community is sufficient to sustain a high level of antibiotic resistance in the population, warn experts in a study published on bmj.com.
Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.
OrbiMed, a leading investment management firm focused on the healthcare sector, is pleased to announce the launch of its next venture capital fund, Caduceus Private Investments IV, LP, with $550 million in limited partner commitments. Approximately 80% of the new fund's capital is from returning investors, and the fund's partners include some of the largest pension plans, endowments, foundations, and sovereign funds globally.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cynthia Lois Tillery Richardson, MSCCCSLP 878 Stonebrook Blvd, Nolensville, TN 37135-9710 Ph: (615) 419-8054 | Cynthia Lois Tillery Richardson, MSCCCSLP 4200 Murfreesboro Pike, Antioch, TN 37013-2789 Ph: (615) 501-3529 |
News Archive
The World Health Organization (WHO) Goodwill Ambassador for Maternal, Newborn and Child Health and supermodel Liya Kebede has highlighted the plight of millions of women and girls living with obstetric fistula.
Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.
Regular prescribing of antibiotics to children in the community is sufficient to sustain a high level of antibiotic resistance in the population, warn experts in a study published on bmj.com.
Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.
OrbiMed, a leading investment management firm focused on the healthcare sector, is pleased to announce the launch of its next venture capital fund, Caduceus Private Investments IV, LP, with $550 million in limited partner commitments. Approximately 80% of the new fund's capital is from returning investors, and the fund's partners include some of the largest pension plans, endowments, foundations, and sovereign funds globally.
› Verified 2 days ago
Linda Le Pham, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 889 Bell Rd Ste A, Antioch, TN 37013 Phone: 800-381-2195 | |
Quilona Robertson, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3409 Daisy Trl, Antioch, TN 37013 Phone: 615-720-1390 | |
Ms. Brandy Micole Drumwright, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2210 Oak Barrel Ln, Antioch, TN 37013 Phone: 615-522-1050 | |
Mrs. Jevetta Latrice Mitchell, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 234 Grovedale Trce, Antioch, TN 37013 Phone: 615-501-0189 | |
Mrs. Christie Renee Beddow, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 100 Brian Cir, Antioch, TN 37013 Phone: 615-751-7284 Fax: 615-301-6196 | |
Deborah Sizemore, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3304 Oak Timber Dr, Antioch, TN 37013 Phone: 918-698-6796 | |
Brittany Mcdonald, CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 889 Bell Rd, Antioch, TN 37013 Phone: 812-617-0492 |